Cannabidiol for different patterns of alcohol use
Effects of Full-spectrum Cannabidiol on Alcohol Consumption and Alcohol Use Disorder Phenotypes: Implications for Precision Medicine
This test will see if taking daily cannabidiol (CBD) helps adults who drink alcohol regularly drink less and have fewer alcohol-related problems.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 21 Years to 65 Years |
| Sex | All |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Trial ID | NCT07279558 on ClinicalTrials.gov |
What this trial studies
Participants are randomized to full-spectrum CBD, broad-spectrum CBD, or placebo and take the assigned medication daily for 8 weeks while completing daily surveys and weekly virtual check-ins. The protocol includes up to five in-person visits over about 13 weeks (screening, medication visit, midpoint, an experimental lab session with alcohol offered in a bar lab, and a final follow-up). The study enrolls adults aged 21–65 who drink regularly and have used CBD or cannabis at least once in the past year. Safety monitoring excludes people on certain interacting or psychotropic medications, pregnant or nursing people, and those with medical conditions that contraindicate CBD or alcohol.
Who should consider this trial
Good fit: Adults 21–65 who regularly drink alcohol, have used CBD or cannabis at least once in the past year, and can attend in-person visits at the study site are the best fit for this protocol.
Not a fit: People who are pregnant or breastfeeding, taking medications that interact with CBD or alcohol, on most antiepileptic or psychotropic drugs, or with medical conditions that make alcohol or CBD unsafe are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this could offer a medication option using CBD to help people reduce drinking and alcohol-related harms.
How similar studies have performed: Early lab and small clinical studies of CBD for alcohol-related behaviors have shown mixed or preliminary signals, so the approach remains relatively unproven in larger clinical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 21-65 2. Have used CBD and cannabis at least once in the last year 3. Regularly drink alcohol 4. Able to provide informed consent and attend in-person study visits Exclusion Criteria: 1. Current use of medications known to have major interaction with Epidiolex, Marinol, or alcohol 2. Current use of antiepileptic medication or any psychotropic medication besides antidepressants 3. Pregnant, nursing, or planning a pregnancy 4. Medical conditions that contraindicates the use of CBD or alcohol 5. Current medical conditions that may require intensive care during the study period Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.
Where this trial is running
Aurora, Colorado
- University of Colorado School of Medicine- Anschutz Medical Campus — Aurora, Colorado, United States (Recruiting)
Study contacts
- Principal investigator: Hollis C Karoly, PhD — University of Colorado School of Medicine- Anschutz Medical Campus
- Study coordinator: Hollis C Karoly, PhD
- Email: hollis.karoly@cuanschutz.edu
- Phone: 303-724-7179
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.